ALBEMARLE CORP — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that ALBEMARLE CORP filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $5.14B | Feb 11, 2026 |
| FY2025 | Dec 31, 2024 | $5.38B | Feb 11, 2026 |
| FY2025 | Dec 31, 2023 | $9.62B | Feb 11, 2026 |
| FY2024 | Dec 31, 2022 | $7.32B | Feb 12, 2025 |
| FY2023 | Dec 31, 2021 | $3.33B | Feb 15, 2024 |
| FY2021 | Dec 31, 2020 | $3.13B | Feb 15, 2023 |
| FY2019 | Dec 31, 2019 | $992.56M | Feb 26, 2020 |
| FY2019 | Sep 30, 2019 | $879.75M | Feb 26, 2020 |
| FY2019 | Jun 30, 2019 | $885.05M | Feb 26, 2020 |
| FY2019 | Mar 31, 2019 | $832.06M | Feb 26, 2020 |
Revenue (Net Sales)
Net sales revenue — gross revenue less returns, allowances, and discounts. Used by many manufacturers and retailers as the primary top-line figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2017 | Dec 31, 2017 | $857.79M | Feb 28, 2018 |
| FY2017 | Sep 30, 2017 | $754.87M | Feb 28, 2018 |
| FY2017 | Jun 30, 2017 | $737.26M | Feb 28, 2018 |
| FY2017 | Mar 31, 2017 | $722.06M | Feb 28, 2018 |
| FY2017 | Dec 31, 2016 | $696.66M | Feb 28, 2018 |
| FY2017 | Sep 30, 2016 | $654.01M | Feb 28, 2018 |
| FY2017 | Jun 30, 2016 | $669.33M | Feb 28, 2018 |
| FY2017 | Mar 31, 2016 | $657.21M | Feb 28, 2018 |
| FY2016 | Dec 31, 2015 | $722.61M | Feb 28, 2017 |
| FY2016 | Sep 30, 2015 | $693.22M | Feb 28, 2017 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $668.72M | Feb 11, 2026 |
| FY2025 | Dec 31, 2024 | $62.54M | Feb 11, 2026 |
| FY2025 | Dec 31, 2023 | $1.19B | Feb 11, 2026 |
| FY2024 | Dec 31, 2022 | $3.07B | Feb 12, 2025 |
| FY2023 | Dec 31, 2021 | $997.97M | Feb 15, 2024 |
| FY2021 | Dec 31, 2020 | $994.85M | Feb 15, 2023 |
| FY2019 | Dec 31, 2019 | $338.51M | Feb 26, 2020 |
| FY2019 | Sep 30, 2019 | $309.87M | Feb 26, 2020 |
| FY2019 | Jun 30, 2019 | $325.91M | Feb 26, 2020 |
| FY2019 | Mar 31, 2019 | $283.49M | Feb 26, 2020 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($510.63M) | Feb 11, 2026 |
| FY2025 | Dec 31, 2024 | ($1.18B) | Feb 11, 2026 |
| FY2025 | Dec 31, 2023 | $1.57B | Feb 11, 2026 |
| FY2024 | Dec 31, 2022 | $2.69B | Feb 12, 2025 |
| FY2023 | Dec 31, 2021 | $123.67M | Feb 15, 2024 |
| FY2021 | Dec 31, 2020 | $375.76M | Feb 15, 2023 |
| FY2019 | Dec 31, 2019 | $90.39M | Feb 26, 2020 |
| FY2019 | Sep 30, 2019 | $155.07M | Feb 26, 2020 |
| FY2019 | Jun 30, 2019 | $154.20M | Feb 26, 2020 |
| FY2019 | Mar 31, 2019 | $133.57M | Feb 26, 2020 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($367.08M) | Feb 11, 2026 |
| FY2025 | Dec 31, 2024 | ($1.78B) | Feb 11, 2026 |
| FY2025 | Dec 31, 2023 | $251.88M | Feb 11, 2026 |
| FY2024 | Dec 31, 2022 | $2.47B | Feb 12, 2025 |
| FY2023 | Dec 31, 2021 | $798.43M | Feb 15, 2024 |
| FY2021 | Dec 31, 2020 | $505.81M | Feb 15, 2023 |
| FY2021 | Dec 31, 2019 | $666.12M | Feb 22, 2022 |
| FY2020 | Dec 31, 2018 | $911.54M | Feb 19, 2021 |
| FY2019 | Dec 31, 2017 | $571.66M | Feb 26, 2020 |
| FY2018 | Dec 31, 2016 | $600.98M | Feb 27, 2019 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $51.40M | Feb 11, 2026 |
| FY2025 | Dec 31, 2024 | $86.72M | Feb 11, 2026 |
| FY2025 | Dec 31, 2023 | $85.73M | Feb 11, 2026 |
| FY2024 | Dec 31, 2022 | $71.98M | Feb 12, 2025 |
| FY2023 | Dec 31, 2021 | $54.03M | Feb 15, 2024 |
| FY2021 | Dec 31, 2020 | $59.21M | Feb 15, 2023 |
| FY2021 | Dec 31, 2019 | $58.29M | Feb 22, 2022 |
| FY2020 | Dec 31, 2018 | $70.05M | Feb 19, 2021 |
| FY2019 | Dec 31, 2017 | $84.33M | Feb 26, 2020 |
| FY2018 | Dec 31, 2016 | $80.48M | Feb 27, 2019 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $550.04M | Feb 11, 2026 |
| FY2025 | Dec 31, 2024 | $618.05M | Feb 11, 2026 |
| FY2025 | Dec 31, 2023 | $910.00M | Feb 11, 2026 |
| FY2024 | Dec 31, 2022 | $524.15M | Feb 12, 2025 |
| FY2023 | Dec 31, 2021 | $441.48M | Feb 15, 2024 |
| FY2021 | Dec 31, 2020 | $429.83M | Feb 15, 2023 |
| FY2021 | Dec 31, 2019 | $533.37M | Feb 22, 2022 |
| FY2020 | Dec 31, 2018 | $446.09M | Feb 19, 2021 |
| FY2019 | Dec 31, 2017 | $450.29M | Feb 26, 2020 |
| FY2018 | Dec 31, 2016 | $353.77M | Feb 27, 2019 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.28B | Feb 11, 2026 |
| FY2025 | Dec 31, 2024 | $687.88M | Feb 11, 2026 |
| FY2025 | Dec 31, 2023 | $1.33B | Feb 11, 2026 |
| FY2024 | Dec 31, 2022 | $1.91B | Feb 12, 2025 |
| FY2023 | Dec 31, 2021 | $344.26M | Feb 15, 2024 |
| FY2021 | Dec 31, 2020 | $798.91M | Feb 15, 2023 |
| FY2021 | Dec 31, 2019 | $719.37M | Feb 22, 2022 |
| FY2020 | Dec 31, 2018 | $546.17M | Feb 19, 2021 |
| FY2019 | Dec 31, 2017 | $303.98M | Feb 26, 2020 |
| FY2018 | Dec 31, 2016 | $735.52M | Feb 27, 2019 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $589.80M | Feb 11, 2026 |
| FY2025 | Dec 31, 2024 | $1.68B | Feb 11, 2026 |
| FY2025 | Dec 31, 2023 | $2.15B | Feb 11, 2026 |
| FY2024 | Dec 31, 2022 | $1.26B | Feb 12, 2025 |
| FY2023 | Dec 31, 2021 | $953.67M | Feb 15, 2024 |
| FY2021 | Dec 31, 2020 | $850.48M | Feb 15, 2023 |
| FY2021 | Dec 31, 2019 | $851.80M | Feb 22, 2022 |
| FY2020 | Dec 31, 2018 | $699.99M | Feb 19, 2021 |
| FY2019 | Dec 31, 2017 | $317.70M | Feb 26, 2020 |
| FY2018 | Dec 31, 2016 | $196.65M | Feb 27, 2019 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $16.37B | Feb 11, 2026 |
| FY2025 | Dec 31, 2024 | $16.61B | Feb 11, 2026 |
| FY2025 | Dec 31, 2023 | $18.27B | Feb 11, 2026 |
| FY2024 | Dec 31, 2022 | $15.46B | Feb 12, 2025 |
| FY2023 | Dec 31, 2021 | $10.97B | Feb 15, 2024 |
| FY2021 | Dec 31, 2020 | $10.45B | Feb 15, 2023 |
| FY2021 | Dec 31, 2019 | $9.86B | Feb 22, 2022 |
| FY2020 | Dec 31, 2018 | $7.58B | Feb 19, 2021 |
| FY2019 | Dec 31, 2017 | $7.75B | Feb 26, 2020 |
| FY2018 | Dec 31, 2016 | $8.16B | Feb 27, 2019 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $9.53B | Feb 11, 2026 |
| FY2025 | Dec 31, 2024 | $9.96B | Feb 11, 2026 |
| FY2024 | Dec 31, 2023 | $9.41B | Feb 12, 2025 |
| FY2023 | Dec 31, 2022 | $7.98B | Feb 15, 2024 |
| FY2021 | Dec 31, 2021 | $5.63B | Feb 15, 2023 |
| FY2021 | Dec 31, 2020 | $4.27B | Feb 22, 2022 |
| FY2020 | Dec 31, 2019 | $3.93B | Feb 19, 2021 |
| FY2019 | Dec 31, 2018 | $3.59B | Feb 26, 2020 |
| FY2018 | Dec 31, 2017 | $3.67B | Feb 27, 2019 |
| FY2017 | Dec 31, 2016 | $3.80B | Feb 28, 2018 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.50B | Feb 11, 2026 |
| FY2025 | Dec 31, 2024 | $1.58B | Feb 11, 2026 |
| FY2025 | Dec 31, 2023 | $1.63B | Feb 11, 2026 |
| FY2024 | Dec 31, 2022 | $1.62B | Feb 12, 2025 |
| FY2023 | Dec 31, 2021 | $1.60B | Feb 15, 2024 |
| FY2021 | Dec 31, 2020 | $1.67B | Feb 15, 2023 |
| FY2021 | Dec 31, 2019 | $1.58B | Feb 22, 2022 |
| FY2020 | Dec 31, 2018 | $1.57B | Feb 19, 2021 |
| FY2019 | Dec 31, 2017 | $1.61B | Feb 26, 2020 |
| FY2018 | Dec 31, 2016 | $1.54B | Feb 27, 2019 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $4.61B | Feb 11, 2026 |
| FY2025 | Dec 31, 2024 | $5.48B | Feb 11, 2026 |
| FY2024 | Dec 31, 2023 | $6.99B | Feb 12, 2025 |
| FY2023 | Dec 31, 2022 | $5.60B | Feb 15, 2024 |
| FY2021 | Dec 31, 2021 | $3.10B | Feb 15, 2023 |
| FY2021 | Dec 31, 2020 | $3.16B | Feb 22, 2022 |
| FY2020 | Dec 31, 2019 | $2.94B | Feb 19, 2021 |
| FY2019 | Dec 31, 2018 | $2.57B | Feb 26, 2020 |
| FY2018 | Dec 31, 2017 | $2.04B | Feb 27, 2019 |
| FY2017 | Dec 31, 2016 | $2.12B | Feb 28, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2019 | Dec 31, 2019 | $613.11M | Feb 26, 2020 |
| FY2019 | Dec 31, 2018 | $555.32M | Feb 26, 2020 |
| FY2019 | Dec 31, 2017 | $1.14B | Feb 26, 2020 |
| FY2019 | Dec 31, 2016 | $2.27B | Feb 26, 2020 |
| FY2018 | Dec 31, 2015 | $213.73M | Feb 27, 2019 |
| FY2017 | Dec 31, 2014 | $2.49B | Feb 28, 2018 |
| FY2016 | Dec 31, 2013 | $477.24M | Feb 28, 2017 |
| FY2015 | Dec 31, 2012 | $477.70M | Feb 29, 2016 |
| FY2014 | Dec 31, 2011 | $469.42M | Mar 2, 2015 |
| FY2013 | Dec 31, 2010 | $529.65M | Feb 25, 2014 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $3.19B | Feb 11, 2026 |
| FY2025 | Dec 31, 2024 | $3.52B | Feb 11, 2026 |
| FY2024 | Dec 31, 2023 | $4.17B | Feb 12, 2025 |
| FY2023 | Dec 31, 2022 | $3.22B | Feb 15, 2024 |
| FY2021 | Dec 31, 2021 | $2.39B | Feb 15, 2023 |
| FY2021 | Dec 31, 2020 | $3.57B | Feb 22, 2022 |
| FY2020 | Dec 31, 2019 | $3.05B | Feb 19, 2021 |
| FY2019 | Dec 31, 2018 | $1.71B | Feb 26, 2020 |
| FY2018 | Dec 31, 2017 | $1.84B | Feb 27, 2019 |
| FY2017 | Dec 31, 2016 | $2.37B | Feb 28, 2018 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (5) | Feb 11, 2026 |
| FY2025 | Dec 31, 2024 | (11) | Feb 11, 2026 |
| FY2025 | Dec 31, 2023 | 13 | Feb 11, 2026 |
| FY2024 | Dec 31, 2022 | 22 | Feb 12, 2025 |
| FY2023 | Dec 31, 2021 | 1 | Feb 15, 2024 |
| FY2021 | Dec 31, 2020 | 3 | Feb 15, 2023 |
| FY2021 | Dec 31, 2019 | 5 | Feb 22, 2022 |
| FY2020 | Dec 31, 2018 | 6 | Feb 19, 2021 |
| FY2019 | Dec 31, 2017 | 0 | Feb 26, 2020 |
| FY2017 | Dec 31, 2016 | 5 | Feb 28, 2018 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (5) | Feb 11, 2026 |
| FY2025 | Dec 31, 2024 | (11) | Feb 11, 2026 |
| FY2025 | Dec 31, 2023 | 13 | Feb 11, 2026 |
| FY2024 | Dec 31, 2022 | 22 | Feb 12, 2025 |
| FY2023 | Dec 31, 2021 | 1 | Feb 15, 2024 |
| FY2021 | Dec 31, 2020 | 3 | Feb 15, 2023 |
| FY2021 | Dec 31, 2019 | 5 | Feb 22, 2022 |
| FY2020 | Dec 31, 2018 | 6 | Feb 19, 2021 |
| FY2019 | Dec 31, 2017 | 0 | Feb 26, 2020 |
| FY2017 | Dec 31, 2016 | 5 | Feb 28, 2018 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 117.72M | Feb 11, 2026 |
| FY2025 | Dec 31, 2024 | 117.56M | Feb 11, 2026 |
| FY2024 | Dec 31, 2023 | 117.36M | Feb 12, 2025 |
| FY2023 | Dec 31, 2022 | 117.17M | Feb 15, 2024 |
| FY2021 | Dec 31, 2021 | 117.02M | Feb 15, 2023 |
| FY2021 | Dec 31, 2020 | 106.84M | Feb 22, 2022 |
| FY2020 | Dec 31, 2019 | 106.04M | Feb 19, 2021 |
| FY2019 | Dec 31, 2018 | 105.62M | Feb 26, 2020 |
| FY2018 | Dec 31, 2017 | 110.55M | Feb 27, 2019 |
| FY2017 | Dec 31, 2016 | 112.52M | Feb 28, 2018 |
Dividends Paid
Cash dividends distributed to common shareholders during the period. Shown as a positive value despite being a cash outflow in the SEC filing.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $190.53M | Feb 11, 2026 |
| FY2025 | Dec 31, 2024 | $188.53M | Feb 11, 2026 |
| FY2025 | Dec 31, 2023 | $187.19M | Feb 11, 2026 |
| FY2024 | Dec 31, 2022 | $184.43M | Feb 12, 2025 |
| FY2023 | Dec 31, 2021 | $177.85M | Feb 15, 2024 |
| FY2021 | Dec 31, 2020 | $161.82M | Feb 15, 2023 |
| FY2021 | Dec 31, 2019 | $152.20M | Feb 22, 2022 |
| FY2020 | Dec 31, 2018 | $144.60M | Feb 19, 2021 |
| FY2019 | Dec 31, 2017 | $140.56M | Feb 26, 2020 |
| FY2018 | Dec 31, 2016 | $135.35M | Feb 27, 2019 |